The feasibility of Chip‐DIA was further demonstrated by using patient‐derived non‐small cell lung cancer (NSCLC) cells to identify potential therapeutic vulnerabilities and suggest drug options for patients with late‐stage NSCLC after developing resistance to third‐generation epidermal growth factor receptor (EGFR) therapy. The gene discussed is EGFR; the disease is lung cancer.